Eli Lilly has announced it will raise the UK price of its diabetes and weight-loss drug Mounjaro by as much as 170 percent, a move affecting out-of-pocket patients and coming as former U.S. President Donald Trump urges pharmaceutical companies to align international drug prices.

The increase has sparked debate over affordability and access in one of the company’s key European markets.